J+J Announce Collaboration to Create Personalised Healthcare Solutions with 3D Printing

Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan to combine their scientific, clinical, material science and technological expertise to

Continue Reading

Johnson & Johnson Exceed Q1 Estimates

Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar.  The negative currency effect is expected to continue to

Continue Reading

J&J Report Strong Second Quarter Results

Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales.  The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain

Continue Reading

Cancer Research Technology, the Institute of Cancer Research and Janssen Partner for Myeloma Drug

Cancer Research Technology (CRT) and the Institute of Cancer Research (ICR) announced earlier today that they have partnered with Johnson & Johnson unit, Janssen Biotech, in an agreement to discover a potential new drug for the blood cancer, multiple myeloma. The partnership is aiming to identify molecules and develop them into experimental therapies that block

Continue Reading

Johnson & Johnson Profits Increase

Johnson & Johnson (J&J) yesterday reported a 12.5% growth in earnings for their first quarter, assisted by sales of new products, the most noticeable being the prostate cancer drug Zytiga. The group’s net earnings came in at $3.91 billion, while turnover fell 0.2% to $16.14 billion.  Worldwide pharmaceutical sales were up 1.2% to $6.13 billion,

Continue Reading